NeuroXT and BIDMC Expand Research Collaboration on AI-Based Alzheimer's Treatment

May 26, 2026
NeuroXT and Beth Israel Deaconess Medical Center have entered a new phase of their collaboration to advance precision treatment for Alzheimer's disease using AI-based neuroimaging biomarkers.

NeuroXT and Beth Israel Deaconess Medical Center have entered a new phase of their collaboration to advance precision treatment for Alzheimer's disease, announced in a press release.

The two organizations completed their initial research that validated NeuroXT's MRI based AI technology for estimating Alzheimer's PET biomarkers. The new agreement expands the study to include data from patients who have received Alzheimer's therapies at BIDMC for over a year, with the goal of improving the clinical use of NeuroXT's imaging biomarkers.

The collaboration continues under the leadership of Dr. Daniel Press, Chief of the Cognitive Neurology Unit at BIDMC, and Dr. Chun Lim, Medical Director of the same unit. NeuroXT also participated in a 2025 BIDMC symposium on new biomarkers in early Alzheimer's disease, which brought together global experts to discuss emerging approaches.

We hope you enjoyed this article.

Consider subscribing to one of our newsletters like Life AI Weekly or Daily AI Brief.

Also, consider following us on social media:

Healthcare & Life Sciences AI AI Brief AI Brief (X)

More from: Life Sciences

05/26
Tata Elxsi Unveils ViTel Material Intelligence Platform for Medical Device Manufacturers
05/26
b.well Connected Health and myTomorrows Partner to Improve Clinical Trial Access
05/26
HkeyBio Expands Wet Lab Validation Capabilities for AI Drug Discovery
05/26
ABILITY Neurotech Receives Approval for Chronic Brain Implant Study in ALS Patients
05/26
Verified Market Research Projects Glucose Tracking App Market to Reach 12 Billion Dollars by 2033

Subscribe to Life AI Weekly

Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.

AI Token Webinar

Market report

AI’s Time-to-Market Quagmire: Why Enterprises Struggle to Scale AI Innovation

ModelOp

The 2025 AI Governance Benchmark Report by ModelOp provides insights from 100 senior AI and data leaders across various industries, highlighting the challenges enterprises face in scaling AI initiatives. The report emphasizes the importance of AI governance and automation in overcoming fragmented systems and inconsistent practices, showcasing how early adoption correlates with faster deployment and stronger ROI.

Read more

You May Also Like